Quantitative analysis for Ascendis Pharma A/S (ASND) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (57.0) (grade B). 31 signals analyzed (25 differentiated alt-data).
ASND stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $228.15 | $221.00 | $222.08 |
| 2026-05-08 | $250.27 | $236.22 | $238.66 |
| 2026-05-20 | $242.08 | $235.50 | $241.34 |
| 2026-06-02 | $222.85 | $215.00 | $216.60 |
| 2026-06-12 | $224.10 | $216.50 | $218.06 |
| 2026-06-25 | $271.89 | $235.51 | $261.58 |
| 2026-07-08 | $277.83 | $265.37 | $277.18 |
| 2026-07-20 | $263.26 | $252.62 | $252.62 |
| 2026-07-30 | $253.07 | $245.84 | $251.07 |
| 2026-08-12 | $258.55 | $251.92 | $255.46 |
| 2026-08-24 | $256.35 | $247.03 | $251.95 |
| 2026-09-03 | $272.44 | $265.80 | $271.12 |
How Ascendis Pharma A/S stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| GMAB | Genmab A/S | $16.7B | — |
| SNN | Smith & Nephew plc | $13.2B | — |
| FMS | Fresenius Medical Care AG & Co. KGaA | $12.0B | — |
| RDY | Dr. Reddy's Laboratories Limited | $11.3B | — |
View all Health Care stocks by valuation and signals →
Ascendis Pharma A/S (ASND) scores Buy (57.0), and the composite conceals a 66-point disagreement between its dimensions. It is strongest on technicals at 88, and weakest on ML forecast at 22. A stock can carry technicals that high while ML forecast sits at 22; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| technicals | 88 |
| valuation | 46 |
| analyst consensus | 42 |
| ML forecast | 22 |
StoQuant analyzes 31 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Ascendis Pharma A/S (ASND): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/ASND"><img src="https://stoquant.com/badge/ASND.svg" alt="Ascendis Pharma A/S (ASND) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.